ClinicalTrials.gg
Enrolling by invitationNCT06215846Updated Nov 26, 2025

A Clinical Study Evaluating the Safety and Efficacy of BioTTT001 in Patients With Malignant Solid Tumors

A Phase 1 interventional study of BioTTT001 injection in Solid Tumor, sponsored by Beijing Bio-Targeting Therapeutics Technology Co., Ltd. Enrolling by invitation at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-11-26.

Sponsored by Beijing Bio-Targeting Therapeutics Technology Co., Ltd · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by May 2026, 5 months ago, but the record still lists the study as enrolling by invitation.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Study summary

This is a Phase 1 open-label study to evaluate the safety, tolerability, and pharmacokinetics of Recombinant Human nsIL12 Oncolytic Adenovirus Injection (BioTTT001) at dose of 5×10∧9VP、5×10∧10VP、5×10∧11VP in Patients With Malignant Solid Tumors. Subjects will be treated with a single dose of BioTTT001 Injection after the screening period.

Read the detailed description

This study is a single arm, open label, single center dose escalation trial. Three study drug dosage groups are pre-set, namely 5 × 10∧9VP、5 × 10∧10VP、 5 × 10∧11VP. According to the principle of dose escalation from low to high, the "3+3" dose escalation method is adopted. In theory, in order to protect the safety of the subjects, during the DLT observation phase of the same dose group, the first subject in each dose group can only be enrolled in the second subject after at least 2 weeks after administration. The DLT observation period for each subject is 28 days after the first administration, and the last subject in each dose group can only enter the next dose escalation after completing the DLT observation period. At least 3 subjects are enrolled in each dose group, and each subject only receives one corresponding dose.

02

Conditions studied

  • Solid Tumor

Keywords

  • Oncolytic virus
  • IL-12
  • Adenovirus
03

In context

Adenoviridae Infections

136 studies on the registry are indexed under Adenoviridae Infections; 34 are open to participants now.

This study's planned enrollment of 12 is below the median of 30 across 109 interventional studies indexed under Adenoviridae Infections.

Browse Adenoviridae Infections studies →

Lead sponsor

Beijing Bio-Targeting Therapeutics Technology Co., Ltd is the lead sponsor of 4 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age range from 18 to 80 years old (including the threshold), no gender restrictions.
  2. Patients with and/or cytologically confirmed malignant solid tumors, who have experienced at least one-line standard treatment failure or intolerance, or lack standard treatment options. Focus on in the head and neck, colorectal cancer, skin malignancies, and cervical cancer.
  3. At least one assessable lesion according to the (RECIST) 1.1.
  4. Assessed by the investigators to have lesions suitable for intratumoral injection (assessable lesions and intratumoral injection lesions can refer to the same lesion).

Exclusion criteria

Exclusion Criteria:

  1. Known allergy to the drug or its components.
  2. Previous treatment with other adenovirus drugs.
  3. Patients with active diseases (such as systemic lupus erythematosus, rheumatoid arthritis, etc.), except type 1 diabetes, hypothyroidism that only needs hormone replacement therapy, and skin diseases that do not need systemic treatment (such as vitiligo, psoriasis or alopecia).
  4. Patients who have not recovered from the adverse reactions of previous treatments (the treatment-related toxicity ≤ grade 2, except for alopecia, pigmentation or other tolerable events judged by the investigator ).
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    BioTTT001 injection

    BioTTT001 is administered as a single Intratumoral injection. The dose groups to be infusion were 5×10\^9 viral particle (VP) ,5×10\^10 VP and 5×10\^11 VP based on the 3+3 dose escalation principle.

    Biological: BioTTT001 injection

Interventions

  • BioTTT001 is administered as a single Intratumoral injection. The dose groups to be infusion were 5×10\^9 VP, 5×10\^10 VP and 5×10\^11 VP based on the 3+3 dose escalation principle.

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events

    The incidence and severity of all types of adverse events evaluated based on NCI-CTCAE V5.0 assessment

    Time frame: 28 days within BioTTT001 injection

  2. MTD

    Maximum tolerated dose (MTD)

    Time frame: 28 days within BioTTT001 injection

Secondary outcomes

  1. Plasma Adenovirus (ADV) copies

    Pharmacokinetic Study (PK): Copies of ADV in plasma at various sampling points.

    Time frame: 28 days within BioTTT001 injection

  2. ADV copies in various sites

    Viral Shedding Analysis: Copies of ADV in swabs of injection sites, rectal swabs, throat swabs, and urine samples at various sampling points.

    Time frame: 28 days within BioTTT001 injection

  3. Serum interleukin-12 (IL-12) level

    Expression levels of IL-12 at various sampling points in serum.

    Time frame: 28 days within BioTTT001 injection

  4. Serum neutralizing antibody level

    Immunogenicity assessment through neutralizing antibody detection.

    Time frame: 28 days within BioTTT001 injection

  5. ORR

    Objective response rate (ORR) as assessed by the investigators.

    Time frame: From date of the first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months

  6. DCR

    Disease control rate (DCR) as assessed by the investigators.

    Time frame: From date of the first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months

  7. PFS

    Progression-free survival (PFS) as assessed by the investigators.

    Time frame: From date of the first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for May 2026, 24 months after the start.

Of 23 phase 1 interventional studies under Adenoviridae Infections, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 101. This study's planned 24 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 27, 2023
First posted
Jan 22, 2024
StartActual
May 7, 2024
Primary completionEst.
May 30, 2026
CompletionEst.
Jun 28, 2026
Last update
Nov 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06215846
Lead sponsor
Beijing Bio-Targeting Therapeutics Technology Co., Ltd
Responsible party
Sponsor
First posted
Jan 22, 2024
Start date
May 7, 2024
Primary completion
May 30, 2026 (estimated)
Completion
Jun 28, 2026 (estimated)
Last update
Nov 26, 2025

Study contacts

Zhenning Wang, MD
principal investigator · The First Affiliated Hospital of China Medical Univeristy
Funan Liu, MD
principal investigator · The First Affiliated Hospital of China Medical Univeristy

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Recombinant Oncolytic Adenovirus 5 Encoding Non-secreting Interleukin-12 BioTTT001

Start the discussion